PATENT CLAIM ANALYSIS

Application Number: 15980431
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "533000"]

Abstract:
The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

Claim (Index 14):
A method of treating a urea cycle disorder in a subject in need thereof, comprising:\n administering to the subject glyceryl tri-[4-phenylbutyrate] (HPN-100) at a first dosage; determining the subject's plasma PAA to PAGN ratio; adjusting the dosage of the glyceryl tri-[4-phenylbutyrate] (HPN-100) based on the subject's plasma PAA to PAGN ratio; and administering to the subject glyceryl tri-[4-phenylbutyrate] (HPN-100) at the adjusted dosage.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.27027
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13610580', '12350111', '14958259', '13417137', '13775000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.81390279753084
- 35 USC 102 Novelty (BERT): 0.6239369773538507
- Combined Prediction Score: 0.7949062155131411
- Mean Citation Score: 452.6015100000001
- Max Citation Score: 534.13275
- Similarity Product: 480.5148790345788

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test